Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
55.06
-5.54 (-9.14%)
At close: Nov 13, 2024, 4:00 PM
55.73
+0.67 (1.22%)
After-hours: Nov 13, 2024, 7:53 PM EST
Viking Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
27
Market Cap
6.14B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.81B |
Bausch + Lomb | 4.68B |
Elanco Animal Health | 4.45B |
RadNet | 1.77B |
Merit Medical Systems | 1.33B |
Legend Biotech | 520.18M |
Blueprint Medicines | 434.42M |
Cytokinetics | 3.22M |
VKTX News
- 1 day ago - Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 - PRNewsWire
- 5 days ago - Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca - CNBC
- 9 days ago - Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results - Investopedia
- 9 days ago - Dow Jones, S&P 500 slip ahead of US elections; NVIDIA, Viking Therapeutics rise while Talen Energy declines - Invezz
- 9 days ago - Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations - Seeking Alpha
- 9 days ago - Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data - Kiplinger
- 9 days ago - Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety - Benzinga
- 9 days ago - Should you buy Viking Therapeutics (VKTX) after today's spike? - Invezz